Eloxx Pharmaceuticals : Webcast and Conference Call

Creating a Leader in Ribosomal RNA-Targeted Genetic Therapy Eloxx Acquires Zikani Therapeutics

April 1, 2021

Forward-looking statements

This presentation contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, including: the development of the Company's readthrough technology; the approval of the Company's patent applications; the Company's ability to successfully defend its intellectual property or obtain necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the Company's ability to obtain applicable regulatory approvals for its current and future product candidates; the acceptance by the market of the Company's products should they receive regulatory approval; the timing and success of the Company's preliminary studies, preclinical research, clinical trials, and related regulatory filings; the ability of the Company to consummate additional financings as needed; the impact of global health concerns, such as the COVID-19 global pandemic, on our ability to continue our clinical and preclinical programs and otherwise operate our business effectively; including successfully integrating the combined companies; as well as those discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

2

Eloxx + Zikani: Positioned to be the world leader in ribosome RNA-targeted genetic therapies

• ELX-02: in Phase 2 development for Cystic Fibrosis (CF)
• Preclinical CF program from Zikani pipeline

• ELX-02 data readout in	Compelling
2H 2021
assets in CF

• Expect to file IND for
  RDEB* and JEB* program in 2022
• Advance programs in inherited and advanced colon cancer targeted at restoring APC* tumor suppressor protein

*RDEB and JEB: Recessive Dystrophic and Junctional Epidermolysis Bullosa

*APC: Adenomatous Polyposis Coli

Strengthened

leadership

Complementary platforms

targeting the human ribosome

Rare disease and oncology pipeline

• President and CEO:
  Sumit Aggarwal
• Head of R&D:
  Dr. Vijay Modur
• TURBO-ZMTM: Proprietary synthetic chemistry platform to design novel macrolide- based oral small molecules
• Ribosome Modulating Agents (RMAs): Potent oral ribosome modulators with favorable therapeutic index

3

Significantly expands and strengthens leadership team

Zikani leadership team to join Eloxx

Sumit Aggarwal

President and CEO

• 20+ years investing and transforming healthcare companies
• Raised >$150M
• Biotech Investor

	Dr. Vijay Modur		Dr. Roger Clark		Daniel Geffken
Head of Research & Development	Head of Discovery Sciences	Interim Chief Financial Officer

• 20+ years in translation	• 20+ years medicinal	• 30+ years building
and drug development	chemistry	companies
• Led Venglustat rare	• Architect of Zikani RMAs	• Closed $2B in equity and
disease program at		debt financings for public
Sanofi		and private companies

4

Transaction overview

Consideration

Board changes

• Eloxx issued ~ 7.6 million shares
• Zikani stockholders have pro forma ownership ~ 16% of Eloxx
• Silvia Noiman, Ph.D., and Martijn Kleijwegt stepped down from Eloxx Board
• Alan Walts, Ph.D., and Raj Parekh, Ph.D., current Zikani directors, appointed to fulfill vacancies and serve out remaining terms

5